These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29866795)

  • 1. Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines.
    Moro PL; Perez-Vilar S; Lewis P; Bryant-Genevier M; Kamiya H; Cano M
    Pediatrics; 2018 Jul; 142(1):. PubMed ID: 29866795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).
    Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS
    Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018.
    Haber P; Moro PL; Ng C; Dores GM; Perez-Vilar S; Marquez PL; Cano M
    Vaccine; 2020 Feb; 38(6):1476-1480. PubMed ID: 31883809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2000 Nov; 49(RR-13):1-8. PubMed ID: 11106289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
    Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
    Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998.
    DuVernoy TS; Braun MM
    Pediatrics; 2000 Oct; 106(4):E52. PubMed ID: 11015547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
    Daley MF; Yih WK; Glanz JM; Hambidge SJ; Narwaney KJ; Yin R; Li L; Nelson JC; Nordin JD; Klein NP; Jacobsen SJ; Weintraub E
    Vaccine; 2014 May; 32(25):3019-24. PubMed ID: 24699471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of endotoxin concentrations in vaccines.
    Geier DA; Geier MR
    Ann Pharmacother; 2002 May; 36(5):776-80. PubMed ID: 11978151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
    Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
    Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.
    Moro PL; Yue X; Lewis P; Haber P; Broder K
    Vaccine; 2011 Nov; 29(50):9404-8. PubMed ID: 21920404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015.
    Moro PL; Cragan J; Tepper N; Zheteyeva Y; Museru O; Lewis P; Broder K
    Vaccine; 2016 Apr; 34(20):2349-53. PubMed ID: 27013434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.